European Journal of Cancer
Volume 39, Issue 13 , Pages 1920-1926 , September 2003

The combination of yondelis and cisplatin is synergistic against human tumor xenografts

  • M. D'Incalci

      Affiliations

    • Department of Oncology, Istituto di Ricerche Farmacologiche “Mario Negri”, Via Eritrea 62, 20157 Milan, Italy
    • SENDO, Via Visconti di Modrone 12, 20122 Milan, Italy
    • Corresponding Author InformationCorresponding author. Tel.; +39-02-3901-4473; fax: +39-02-354-6277
    • ,
  • T. Colombo

      Affiliations

    • Department of Oncology, Istituto di Ricerche Farmacologiche “Mario Negri”, Via Eritrea 62, 20157 Milan, Italy
    • ,
  • P. Ubezio

      Affiliations

    • Department of Oncology, Istituto di Ricerche Farmacologiche “Mario Negri”, Via Eritrea 62, 20157 Milan, Italy
    • ,
  • I. Nicoletti

      Affiliations

    • Department of Oncology, Istituto di Ricerche Farmacologiche “Mario Negri”, Laboratori Negri Bergamo, Via Gavazzeni 11, 24125 Bergamo, Italy
    • ,
  • R. Giavazzi

      Affiliations

    • Department of Oncology, Istituto di Ricerche Farmacologiche “Mario Negri”, Laboratori Negri Bergamo, Via Gavazzeni 11, 24125 Bergamo, Italy
    • SENDO, Via Visconti di Modrone 12, 20122 Milan, Italy
    • ,
  • E. Erba

      Affiliations

    • Department of Oncology, Istituto di Ricerche Farmacologiche “Mario Negri”, Via Eritrea 62, 20157 Milan, Italy
    • ,
  • L. Ferrarese

      Affiliations

    • Department of Oncology, Istituto di Ricerche Farmacologiche “Mario Negri”, Via Eritrea 62, 20157 Milan, Italy
    • ,
  • D. Meco

      Affiliations

    • Division of Pediatric Oncology, Policlinico Universitario A. Gemelli, Largo A.Gemelli 8, 00168 Rome, Italy
    • ,
  • R. Riccardi

      Affiliations

    • Division of Pediatric Oncology, Policlinico Universitario A. Gemelli, Largo A.Gemelli 8, 00168 Rome, Italy
    • ,
  • C. Sessa

      Affiliations

    • SENDO, Via Visconti di Modrone 12, 20122 Milan, Italy
    • ,
  • E. Cavallini

      Affiliations

    • Department of Oncology, Istituto di Ricerche Farmacologiche “Mario Negri”, Via Eritrea 62, 20157 Milan, Italy
    • ,
  • J. Jimeno

      Affiliations

    • Pharma Mar, S.A., Poligono Industrial La Mina, Avda. de Los Reyes 1, 28770 Colmenar Viejo, Madrid, Spain
    • ,
  • G.T. Faircloth

      Affiliations

    • Pharma Mar USA, Inc., 320 Putnam Avenue, Cambridge, MA 02139-4616, USA

Received 10 April 2003 ,Accepted 13 May 2003.

References 

  1. Rinehart KL, Holt TG, Fregeau NL, et al.  Ecteinascidins 729, 743, 745, 759A, 759B, and 770 (potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinate). J. Org. Chem. 1990;55:4512–4515
  2. Guan Y, Sakai R, Rinehart KL, Wang AHJ. Molecular and crystal structures of ecteinascidins (potent antitumor compounds from the Caribbean tunicate Ecteinascidia turbinate). J. Biomol. Struct. Dyn. 1993;10:793–818
  3. Jimeno JM, Faircloth G, Cameron L, et al.  Progress in the acquisition of new marine-derived anticancer compounds (development of ecteinascidin-743 (ET-743)). Drugs Future. 1996;21:1155–1165
  4. Valoti G, Nicoletti MI, Pellegrino A, et al.  Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clin. Cancer Res. 1998;4:1977–1983
  5. Hendriks HR, Fiebig HH, Giavazzi R, Langdon SP, Jimeno JM, Faircloth GT. High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer. Ann. Oncol. 1999;10:1233–1240
  6. Ghielmini M, Colli E, Erba E, et al.  In vitro schedule-dependency of myelotoxicity and cytotoxicity of Ecteinascidin 743 (ET-743). Ann. Oncol. 1998;9:989–993
  7. Izbicka E, Lawrence R, Raymond E, et al.  In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. Ann. Oncol. 1998;9:981–987
  8. Li WW, Takahashi N, Jhanwar S, Cordon-Cardo C, et al.  Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents (identification of ecteinascidin-743 as a potent cytotoxic agent). Clin. Cancer Res. 2001;7:2908–2911
  9. Taamma A, Misset JL, Riofrio M, et al.  Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J. Clin. Oncol. 2001;19:1256–1265
  10. Delaloge S, Yovine A, Taamma A, et al.  Ecteinascidin-743 (a marine-derived compound in advanced, pretreated sarcoma patients—preliminary evidence of activity). J. Clin. Oncol. 2001;19:1248–1255
  11. Demetri GD. ET-743 (the US experience in sarcomas of soft tissues). Anticancer Drugs. 2002;13(Suppl. 1):S7–S9
  12. Brain EG. Safety and efficacy of ET-743 (the French experience). Anticancer Drugs. 2002;13(Suppl. 1):S11–S14
  13. D'Incalci M, Erba E, Damia G, et al.  Unique features of the mode of action of ET-743. Oncologist. 2002;7:210–216
  14. Zwelling LA, Anderson T, Kohn KW. DNA-protein and DNA interstrand cross-linking by cis- and trans-platinum(II) diamminedichloride in L1210 mouse leukemia cells and relation to cytotoxicity. Cancer Res. 1979;39:365–369
  15. Plooy AC, van Dijk M, Lohman PH. Induction and repair of DNA cross-links in chinese hamster ovary cells treated with various platinum coordination compounds in relation to platinum binding to DNA, cytotoxicity, mutagenicity, and antitumor activity. Cancer Res. 1984;44:2043–2051
  16. Cohen SM, Lippard SJ. Cisplatin (from DNA damage to cancer chemotherapy). Prog. Nucleic. Acid. Res. Mol. Biol. 2001;67:93–130
  17. Pommier Y, Kohlhagen G, Bailly C, Waring M, Mazumder A, Kohn KW. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the caribbean tunicate Ecteinascidia turbinate. Biochemistry. 1996;35:13303–13309
  18. Fink D, Zheng H, Nebel S, et al.  In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res. 1997;57:1841–1845
  19. Damia G, Silvestri S, Carrassa L, et al.  Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int. J. Cancer. 2001;92:583–588
  20. Erba E, Bergamaschi D, Bassano L, et al.  Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur. J. Cancer. 2001;37:97–105
  21. Takebayashi Y, Pourquier P, Zimonjic DB, et al.  Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat. Med. 2001;7:961–966
  22. Zewail-Foote M, Li VS, Kohn H, Bearss D, Guzman M, Hurley LH. The inefficiency of incisions of ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent. Chem. Biol. 2001;8:1033–1049
  23. Berenbaum MC. The expected effect of a combination of agents (the general solution). J. Theor. Biol. 1985;114:413–431
  24. Meco D, Colombo T, Ubezio P, et al. Effective combination of ET-743 and doxorubicin in sarcoma. Preclinical studies. Cancer Chemother Pharmacol [in press].
  25. Masazza G, Lucchini V, Tomasoni A, et al.  Malignant behavior and resistance to cisplatin of human ovarian carcinoma xenografts established from the same patient at different stages of the disease. Cancer Res. 1991;51:6358–6362
  26. Belotti D, Rieppi M, Nicoletti MI, et al.  Paclitaxel (Taxol(R)) inhibits motility of paclitaxel-resistant human ovarian carcinoma cells. Clin. Cancer Res. 1996;2:1725–1730
  27. Nicoletti MI, Lucchini V, Massazza G, Abbott BJ, D'Incalci M, Giavazzi R. Antitumor activity of taxol (NSC-125973) in human ovarian carcinomas growing in the peritoneal cavity of nude mice. Ann. Oncol. 1993;4:151–155
  28. Villalona-Calero MA, Eckhardt SG, Weiss G, et al.  A phase I and pharmacokinetic study of ecteinascidin-743 on a daily ×5 schedule in patients with solid malignancies. Clin. Cancer Res. 2002;8:75–85
  29. Rozencweig M, von Hoff DD, Slavik M, Muggia FM. Cis-diamminedichloroplatinum (II). A new anticancer drug. Ann. Intern. Med. 1977;86:803–812
  30. Sessa C, Colombo N, Bauer J, et al.  Phase II study of salvage ET-743 given as 3-hr infusion in ovarian cancer (OC) patients. Ann. Oncol. 2002;13(Suppl. 5):109; [abstr]

PII: S0959-8049(03)00490-8

doi: 10.1016/S0959-8049(03)00490-8

European Journal of Cancer
Volume 39, Issue 13 , Pages 1920-1926 , September 2003

Article Tools

* Image Usage & Resolution